Scarica l'app Stockscreener
16.84
4.91%
-0.87
Dopo l'orario di chiusura:
16.84
Precedente Chiudi:
$17.71
Aprire:
$17.65
Volume 24 ore:
735.55K
Relative Volume:
0.78
Capitalizzazione di mercato:
$516.43M
Reddito:
$17.16M
Utile/perdita netta:
$-163.62M
Rapporto P/E:
-2.7697
EPS:
-6.08
Flusso di cassa netto:
$-121.61M
1 W Prestazione:
+2.68%
1M Prestazione:
-12.70%
6M Prestazione:
-58.24%
1 anno Prestazione:
-31.79%
Intervallo 1D:
$16.79
$18.08
Intervallo di 1 settimana:
$15.78
$18.50
Portata 52W:
$12.21
$41.31
Anaptysbio Inc Stock (ANAB) Company Profile
Nome
Anaptysbio Inc
Settore
Industria
Telefono
858-362-6295
Indirizzo
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Confronta ANAB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
16.84 | 516.43M | 17.16M | -163.62M | -121.61M | -6.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-04 | Iniziato | Wolfe Research | Outperform |
| 2024-12-11 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-07-22 | Iniziato | H.C. Wainwright | Buy |
| 2024-07-19 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-04-16 | Iniziato | Leerink Partners | Outperform |
| 2024-04-11 | Iniziato | Wells Fargo | Overweight |
| 2024-03-12 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2024-02-26 | Iniziato | BTIG Research | Buy |
| 2024-02-21 | Iniziato | Stifel | Buy |
| 2024-02-16 | Iniziato | Piper Sandler | Overweight |
| 2023-05-22 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-05-18 | Iniziato | TD Cowen | Outperform |
| 2023-01-06 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-09-19 | Ripresa | H.C. Wainwright | Buy |
| 2022-09-13 | Downgrade | Truist | Buy → Hold |
| 2022-09-01 | Iniziato | Raymond James | Outperform |
| 2022-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-06-22 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-21 | Iniziato | UBS | Neutral |
| 2021-03-16 | Aggiornamento | Truist | Hold → Buy |
| 2021-03-09 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-03-08 | Downgrade | JP Morgan | Overweight → Underweight |
| 2021-02-11 | Aggiornamento | JP Morgan | Underweight → Overweight |
| 2020-10-27 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2020-10-14 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-11-08 | Downgrade | JP Morgan | Overweight → Underweight |
| 2019-11-08 | Downgrade | Jefferies | Buy → Hold |
| 2019-11-08 | Downgrade | SunTrust | Buy → Hold |
| 2019-11-08 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-06-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | Downgrade | Stifel | Buy → Hold |
| 2018-12-20 | Iniziato | H.C. Wainwright | Buy |
| 2018-11-21 | Iniziato | JP Morgan | Overweight |
| 2018-07-19 | Iniziato | Credit Suisse | Outperform |
| 2018-04-04 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | Reiterato | Stifel | Buy |
| 2018-03-06 | Reiterato | Stifel | Buy |
| 2018-02-15 | Reiterato | SunTrust | Buy |
| 2018-01-23 | Reiterato | Credit Suisse | Outperform |
| 2017-11-15 | Iniziato | SunTrust | Buy |
| 2017-11-09 | Iniziato | Jefferies | Buy |
| 2017-10-11 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Anaptysbio Inc Borsa (ANAB) Ultime notizie
AnaptysBio (NASDAQ:ANAB) Price Target Raised to $42.00 - MarketBeat
Rhumbline Advisers Grows Position in AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
HC Wainwright Reaffirms Neutral Rating for AnaptysBio (NASDAQ:ANAB) - MarketBeat
When (ANAB) Moves Investors should Listen - Stock Traders Daily
Y Intercept Hong Kong Ltd Purchases Shares of 23,497 AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio (NASDAQ:ANAB) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - Defense World
Leerink Partnrs Weighs in on AnaptysBio FY2029 Earnings - MarketBeat
AnaptysBio (ANAB) to Release Quarterly Earnings on Monday - MarketBeat
AnaptysBio: A Shadow Of Its Former Self (NASDAQ:ANAB) - Seeking Alpha
Palmoplantar Pustulosis Clinical and Non-Clinical Studies, - openPR
AnaptysBio’s (ANAB) Neutral Rating Reaffirmed at HC Wainwright - Defense World
AnaptysBio, Inc. (NASDAQ:ANAB) Short Interest Update - MarketBeat
AnaptysBio (NASDAQ:ANAB) Shares Gap Up Following Strong Earnings - MarketBeat
H.C. Wainwright maintains AnaptysBio stock Neutral with $22 target By Investing.com - Investing.com Canada
Where AnaptysBio Stands With Analysts - Benzinga
AnaptysBio (ANAB) Expected to Announce Earnings on Monday - Defense World
AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates - MSN
AnaptysBio (NASDAQ:ANAB) Shares Gap Up Following Better-Than-Expected Earnings - Defense World
AnaptysBio, Inc. (NASDAQ:ANAB) Sees Large Growth in Short Interest - Defense World
AnaptysBio (NASDAQ:ANAB) Issues Earnings Results - MarketBeat
Analysts Set AnaptysBio, Inc. (NASDAQ:ANAB) PT at $36.20 - MarketBeat
AnaptysBio Reports Strong Progress in Clinical Trials - TipRanks
AnaptysBio’s Promising Clinical Trials and Strong Financial Position Earn ‘Buy’ Rating from Analyst - TipRanks
AnaptysBio reports Q4 EPS (72c), consensus ($1.70) - TipRanks
AnaptysBio, Inc. (ANAB) Tops Q4 EPS by 90c - StreetInsider.com
ANAPTYSBIO, INC SEC 10-K Report - TradingView
Anaptys Announces Participation in March Investor Conferences - The Manila Times
AnaptysBio's Rosnilimab Achieves Highest-Ever RA Treatment Response RateWhat Does This Mean for Investors? - StockTitan
Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire
(ANAB) Investment Analysis - Stock Traders Daily
AnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
AnaptysBio (NASDAQ:ANAB) Stock Price Down 5.7%Here's What Happened - MarketBeat
What is HC Wainwright's Estimate for AnaptysBio Q1 Earnings? - MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB) Short Interest Down 8.6% in January - Defense World
AnaptysBio (ANAB) Surges 30.5%: Is This an Indication of Further Gains? - MSN
What is HC Wainwright’s Forecast for AnaptysBio Q1 Earnings? - Armenian Reporter
AnaptysBio (NASDAQ:ANAB) Price Target Raised to $51.00 - MarketBeat
AnaptysBio (NASDAQ:ANAB) Trading Up 16.5% After Analyst Upgrade - MarketBeat
Q1 Earnings Estimate for AnaptysBio Issued By HC Wainwright - Defense World
Wedbush Reaffirms Outperform Rating for AnaptysBio (NASDAQ:ANAB) - MarketBeat
AnaptysBio (NASDAQ:ANAB) Given New $51.00 Price Target at Wells Fargo & Company - Armenian Reporter
Anaptysbio Inc Azioni (ANAB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.39%
0.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):